普莱柯(603566.SH)：子公司获得新兽药注册证书

Core Viewpoint - The approval of a new veterinary drug, a trivalent inactivated vaccine for Newcastle disease, avian influenza (H9 subtype), and infectious bursal disease, represents a significant advancement for the poultry industry, addressing critical diseases that cause substantial economic losses [1] Company Summary - The company,普莱柯 (603566.SH), announced the approval of its wholly-owned subsidiary, 洛阳惠中生物技术有限公司, for a new veterinary drug [1] - The new vaccine is officially registered as of January 12, 2026, under the Ministry of Agriculture and Rural Affairs of the People's Republic of China [1] Industry Summary - Newcastle disease, avian influenza (H9 subtype), and infectious bursal disease are major infectious diseases that severely impact the poultry industry, leading to significant economic losses [1] - The new trivalent inactivated vaccine offers several advantages: 1. Utilizes suspension cell culture technology for more controllable and efficient production [1] 2. Achieves high soluble expression of VP2 protein for infectious bursal disease in a baculovirus vector [1] 3. Provides immunity lasting over 4 months and allows for multi-disease prevention with a single injection, reducing stress on chicken populations from frequent vaccinations [1]